Search research articles
Contact Us
Filters
Showing results (11-20 of 228) with videos related to
Page
of 23
Sort By:
ACG Case Reports Journal
|
October 17, 2019
Correction: Colonic Vascular Prominence From Superior Mesenteric Vein Occlusion
Thurarshen Jeyalingam, Kevin Pivovarov, Mark S Silverberg
Molecular Diagnosis & Therapy
|
August 29, 2009
The future of molecular approaches to inflammatory bowel disease
Boyko Kabakchiev, Smita Halder, Mark S Silverberg
ACG Case Reports Journal
|
December 5, 2019
Colonic Vascular Prominence From Superior Mesenteric Vein Occlusion
Thurarshen Jeyalingam, Kevin Pivovarov, Mark S Silverberg
Gastroenterology
|
August 18, 2020
What Constitutes Frailty In Inflammatory Bowel Disease?
Margaret Walshe, Mark S Silverberg, Laura E Targownik
Canadian Journal of Gastroenterology & Hepatology
|
May 13, 2015
Biomarkers as potential treatment targets in inflammatory bowel disease: A systematic review
Travis Murdoch, Sarah O'Donnell, Mark S Silverberg, et al.
The American Journal of Gastroenterology
|
April 23, 2014
Analyzing the human microbiome: a "how to" guide for physicians
Andrea D Tyler, Michelle I Smith, Mark S Silverberg
Inflammatory Bowel Diseases
|
April 27, 2018
Higher Infliximab Levels Are Not Associated With an Increase in Adverse Events in Inflammatory Bowel Disease
Tomer Greener, Boyko Kabakchiev, A Hillary Steinhart, et al.
Journal of Crohn'S & Colitis
|
April 17, 2018
Accelerated Clearance of Infliximab is Associated With Treatment Failure in Patients With Corticosteroid-Refractory Acute Ulcerative Colitis
David Kevans, Sanjay Murthy, Diane R Mould, et al.
Journal of Crohn'S & Colitis
|
January 3, 2018
The Unfinished Symphony: Golimumab Therapy for Anti-Tumour Necrosis Factor Refractory Crohn's Disease
Tomer Greener, Karen Boland, A Hillary Steinhart, et al.
Journal of Crohn'S & Colitis
|
June 28, 2015
Higher Rates of Dose Optimisation for Infliximab Responders in Ulcerative Colitis than in Crohn's disease
Sarah O'Donnell, Joanne M Stempak, A Hillary Steinhart, et al.
Page
of 23
Search research articles
Search
Showing results (11-20 of 228) with videos related to
Sort By:
Page
of 23
ACG Case Reports Journal
|
October 17, 2019
Correction: Colonic Vascular Prominence From Superior Mesenteric Vein Occlusion
Thurarshen Jeyalingam, Kevin Pivovarov, Mark S Silverberg
Molecular Diagnosis & Therapy
|
August 29, 2009
The future of molecular approaches to inflammatory bowel disease
Boyko Kabakchiev, Smita Halder, Mark S Silverberg
ACG Case Reports Journal
|
December 5, 2019
Colonic Vascular Prominence From Superior Mesenteric Vein Occlusion
Thurarshen Jeyalingam, Kevin Pivovarov, Mark S Silverberg
Gastroenterology
|
August 18, 2020
What Constitutes Frailty In Inflammatory Bowel Disease?
Margaret Walshe, Mark S Silverberg, Laura E Targownik
Canadian Journal of Gastroenterology & Hepatology
|
May 13, 2015
Biomarkers as potential treatment targets in inflammatory bowel disease: A systematic review
Travis Murdoch, Sarah O'Donnell, Mark S Silverberg, et al.
The American Journal of Gastroenterology
|
April 23, 2014
Analyzing the human microbiome: a "how to" guide for physicians
Andrea D Tyler, Michelle I Smith, Mark S Silverberg
Inflammatory Bowel Diseases
|
April 27, 2018
Higher Infliximab Levels Are Not Associated With an Increase in Adverse Events in Inflammatory Bowel Disease
Tomer Greener, Boyko Kabakchiev, A Hillary Steinhart, et al.
Journal of Crohn'S & Colitis
|
April 17, 2018
Accelerated Clearance of Infliximab is Associated With Treatment Failure in Patients With Corticosteroid-Refractory Acute Ulcerative Colitis
David Kevans, Sanjay Murthy, Diane R Mould, et al.
Journal of Crohn'S & Colitis
|
January 3, 2018
The Unfinished Symphony: Golimumab Therapy for Anti-Tumour Necrosis Factor Refractory Crohn's Disease
Tomer Greener, Karen Boland, A Hillary Steinhart, et al.
Journal of Crohn'S & Colitis
|
June 28, 2015
Higher Rates of Dose Optimisation for Infliximab Responders in Ulcerative Colitis than in Crohn's disease
Sarah O'Donnell, Joanne M Stempak, A Hillary Steinhart, et al.
Page
of 23